Approval · Notice of Compliance 12926 · 2012
TEVA-NARATRIPTAN: Notice of Compliance 12926
Issued January 13, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12926
- Date
- January 13, 2012
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
- Canadian reference product
- AMERGE
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-NARATRIPTAN | 02314290 | Marketed |
| TEVA-NARATRIPTAN | 02314304 | Marketed |
Medicinal ingredients
- NARATRIPTAN HCL 1 MG per TAB
- NARATRIPTAN HCL 2.5 MG per TAB